Wide Ranks

GHRS

GH Research PLC

9.28

Top Statistics
Market Cap 482 M Forward PE -9.37 Revenue Growth 0.00 %
Current Ratio 19.60 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -6.94 Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 151 M Total Cash Per Share 2.91 Total Debt 760000
Total Debt To Equity 0.3830 Current Ratio 19.60 Book Value Per Share 4.21
All Measures
Short Ratio 3057.00 % Message Board Id finmb_707594028 Shares Short Prior Month 1 M
Return On Equity -0.1620 City Dublin Uuid c55fe4aa-a267-3808-8a6d-44adac7d7d7b
Previous Close 9.10 First Trade Date Epoch Utc 1 B Book Value 4.21
Beta 0.7410 Total Debt 760000 Volume 58124
Price To Book 2.20 Fifty Two Week Low 5.05 Total Cash Per Share 2.91
Shares Short Previous Month Date 1 B Target Median Price 33.50 Max Age 86400
Recommendation Mean 1.40 Sand P52 Week Change 0.3133 Target Mean Price 31.25
Net Income To Common -34966000 Short Percent Of Float 0.1289 Implied Shares Outstanding 52 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 82110
Average Volume10days 82110 Total Cash 151 M Next Fiscal Year End 1 B
Held Percent Insiders 0.4039 Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Regular Market Previous Close 9.10 Target Low Price 18.00
Gmt Off Set Milliseconds -18000000 Fifty Day Average 7.98 Open 9.16
Free Cashflow -26513750 Dividend Yield 0.00 % Return On Assets -0.1274
Time Zone Short Name EST Trailing Eps -0.7900 Day Low 8.67
Address1 Joshua Dawson House Shares Outstanding 52 M Price Hint 2
Target High Price 40.00 Website https://www.ghres.com 52 Week Change 0.4872
Average Volume 58443 Forward Eps -1.15 Recommendation Key strong_buy
Quick Ratio 1939.40 % Is_sp_500 False Regular Market Day High 9.40
Profit Margins 0.00 % Debt To Equity 0.3830 Fifty Two Week High 14.99
Day High 9.40 Shares Short 1 M Regular Market Open 9.16
Industry Key biotechnology Earnings Growth 0.00 % Revenue Growth 0.00 %
Shares Percent Shares Out 0.0367 Operating Cashflow -37957000 Currency USD
Time Zone Full Name America/New_York Market Cap 482 M Is_nasdaq_100 False
Zip D02 RY95 Quote Type EQUITY Industry Biotechnology
Long Name GH Research PLC Regular Market Day Low 8.67 Held Percent Institutions 0.5915
Current Price 9.28 Address2 Dawson Street Enterprise To Ebitda -6.94
Financial Currency USD Current Ratio 19.60 Industry Disp Biotechnology
Number Of Analyst Opinions 4 Country Ireland Float Shares 10 M
Two Hundred Day Average 10.19 Enterprise Value 316 M Forward PE -9.37
Regular Market Volume 58124 Ebitda -45526000 Exchange NGM
Go to Yahoo Finance Go to Seeking Alpha 
GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders.

It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).

The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression.

It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders.

The company was founded in 2018 and is based in Dublin, Ireland.